Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase

PURPOSE: We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. METHODS: Nilotinib was given at 300 mg or 400 mg twice daily. Serum concentration data (sparse and full pharmacok...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Clin Pharmacol
Egile Nagusiak: Larson, Richard A., Yin, Ophelia Q. P., Hochhaus, Andreas, Saglio, Giuseppe, Clark, Richard E., Nakamae, Hirohisa, Gallagher, Neil J., Demirhan, Eren, Hughes, Timothy P., Kantarjian, Hagop M., le Coutre, Philipp D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5557053/
https://ncbi.nlm.nih.gov/pubmed/22207416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-011-1200-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak